GENEVA (AP) — Swiss pharmaceuticals group Novartis says net income fell 15 percent in the first quarter, as it continued to adjust to generic competition for its Gleevec leukemia drug and stopped work on a hoped-for treatment for heart failure.
www.stltoday.com - RSS Results in business* of type article, St. Louis Post-Dispatch: Business
Mon, 04/24/2017 - 11:53pm
GENEVA (AP) — Swiss pharmaceuticals group Novartis says net income fell 15 percent in the first quarter, as it continued to adjust to generic competition for its Gleevec leukemia drug and stopped work on a hoped-for treatment for heart failure.